Video

PD-L1: An Important, But Imperfect Biomarker

Author(s):

H. Jack West, M.D.

Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.

In the lung cancer space, PD-L1 is not a perfect biomarker, says H. Jack West, M.D., thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center.

PD-L1, a protein that immunotherapy drugs such as Keytruda (pembrolizumab) and Imfinzi (durvalumab) target, may not be as powerful a biomarker as ALK and EGFR. While PD-L1 status is often used to determine which patients should receive certain immunotherapy drugs, clinicians like West have also seen good promising response rates for patients given these agents who test low or negative for PD-L1.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Related Content
Illustration of lungs.
February 4th 2025

Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials

Spencer Feldman
Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lung cancer.
January 28th 2025

Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC

Ryan Scott
The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of woman with brown hair.
January 23rd 2025

Matching Patient Needs with Oncologists’ Strengths in Cancer Care

Sue McCarthy
Following a lung cancer diagnosis, I learned that it is important to ask oncologists thoughtful questions to know if they are the best doctor for my needs.
Image of lung cancer awareness.
January 21st 2025

The Power of Unity: Why the Lung Cancer Genetics Study Matters

Jill Feldman
The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of lung cancer